GeneralConnection.com ➔ Dictionary
Dictionary Search

haemophilia b

Synonyms

Noun

1. hemophilia B

2. haemophilia B, Christmas disease, hemophilia, haemophilia, bleeder's disease

Usage
Pfizer receives EC approval for Hympavzi to treat haemophilia - Yahoo
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors - Business Wire
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
Building safeguards for gene therapy in haemophilia - The Lancet
HHS pharmacy sets national benchmark: First-ever delivery of groundbreaking $4.5M Hemophilia B treatment - Hospital News
Marstacimab in the treatment of patients with hemophilia A and B - Via Medica Journals
Exploring gene editing as a potential therapeutic strategy for hemophilia - Frontiers
Gene therapy can help reduce joint bleeds in hemophilia B: New data - Hemophilia News Today
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Hemophilia B Pipeline 2026 Report Highlights Next-Gen Gene Therapies, FDA Advances, and Clinical Momentum Across Novo Nordisk, Pfizer, Sanofi & Emerging Biotechs | DelveInsight - Barchart.com
Netherlands Temporarily Includes Hympavzi in Basic Package for Hemophilia A & B - NAVLIN DAILY
4 Things to Expect for the Future of Hemophilia Treatment - Docwire News
Hull teenager first to be treated with new haemophilia drug - BBC
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B - PharmTech.com
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
New gene therapy reduces bleeding rates for hemophilia B patients - Hemophilia News Today
(marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need - Business Wire
Marstacimab Superior to On-Demand Prophylaxis for Hemophilia A, B, With Inhibitors - Docwire News
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients - PMLiVE
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Five-year study confirms durable efficacy of etranacogene dezaparvovec - PharmaTimes
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors - Business Wire
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Lighting up the library for World Haemophilia Day 2026 - Birmingham City Council
Haemophilia A vs B: Which is more severe? Here’s what sets them apart - TheHealthSite
How pioneering gene therapy changed the life of the first man in Wales to receive it - Nation.Cymru
Man battling disease since he was a baby incredibly no longer needs weekly treatment - Wales Online
CSL’s haemophilia therapy shows durable five-year benefits in landmark trial results - BiotechDispatch
How durable is gene therapy for haemophilia B? - Nature
Groundbreaking treatment for haemophilia administered in Wales for first time - Nation.Cymru
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
First patient in Wales receives ground-breaking gene therapy treatment - Nation.Cymru
‘A game-changer for our son’: City teen first in UK to be treated with new haemophilia drug - The Hull Story
Haemophilia injections hailed as ‘real step forward’ for sufferers - STV News
Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study - The New England Journal of Medicine
Phase 3 Analysis: Concizumab Noninferior to Prior Prophylaxis in Hemophilia A, B, Without Inhibitors - Docwire News
World Haemophilia Day: Over 5,000 Kenyans living with blood disorder - KBC Digital
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Exploring Eptacog Beta Dosing in Patients With Hemophilia A or B - Docwire News
Patients With Hemophilia Face Significant Burden Despite Treatment Type or Disease Severity - Docwire News
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
First German haemophilia B patient receives gene therapy HEMGENIX - PharmaTimes
Hemophilia B gene therapy benefits last more than a decade: Study - Hemophilia News Today
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
First-in-human trial of hemophilia B treatment BE-101 starts dosing - Hemophilia News Today
Wolfgang Miesbach: New Study on AAV5 Antibodies in Haemophilia B Gene Therapy - Oncodaily
Hull teenager with haemophilia is first in the country to be treated with ‘game-changing’ drug - Hull Live
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B - The New England Journal of Medicine
With hemophilia B, a lifetime of worry eased with one infusion - Penn Today
NICE recommends weekly injection for severe haemophilia B - The Pharmaceutical Journal
Non-replacement therapy for people with haemophilia B: another step towards health equity - The Lancet
CSL Behring treats two patients with gene therapy for haemophilia B - Clinical Trials Arena
NMPA approves BBM and Takeda China’s haemophilia B therapy - Pharmaceutical Technology
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Eloctate, Alprolix control bleeds in hemophilia patients’ major surgeries - Hemophilia News Today
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors - PR Newswire
Transformational therapy cures haemophilia B - BBC
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system - Nature
Spotlight on the ISTH Hemophilia Treatment Guidelines and Alternate Recommendations - Hematology Advisor
Haemophilia gene therapy patients thriving over a decade after treatment | UCL News - UCL - UCL | University College London
Hemophilia gene therapy: A new era of treatment and the obstacles ahead - Drug Discovery News
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations - Managed Healthcare Executive
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors - The New England Journal of Medicine
Hemophilia prognosis: Life expectancy and outlook - Hemophilia News Today
Belief, Takeda’s home-grown haemophilia B gene therapy gains nod in China - FirstWord Pharma
How to Plan for Emergencies When You Have Hemophilia B - Everyday Health
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
One dose of gene therapy gives years of relief from blood disorder - Nature
China Explores Weight-Based Pricing for First Domestic Hemophilia B Gene Therapy - NAVLIN DAILY
Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use - PMLiVE
Extended hemophilia half-life products aid care, but raise costs - Hemophilia News Today
Real Stories from People Living with Hemophilia - Centers for Disease Control and Prevention | CDC (.gov)
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice - Nature
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B - Yahoo Finance
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
Freeline Therapeutics doses first subject in haemophilia B therapy trial - Clinical Trials Arena
Haemophilia - The Lancet
Gene therapy trial markedly cuts bleeding risk in haemophilia B patients - The Guardian
EVOLVING THE TREATMENT LANDSCAPE WITH THE FIRST THERAPY APPROVED FOR PEOPLE WITH HEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS - AJMC
Gene Therapy for Hemophilia B Could Lower Health Plans’ Budget Over Time - AJMC
uniQure announces FDA approval of first gene therapy for adults with hemophilia B - uniqure.gcs-web.com
Pfizer reports positive results from Phase III BASIS trial for haemophilia - Clinical Trials Arena
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
How Fitusiran Changes the Treatment Landscape in Hemophilia: Guy Young, MD - AJMC
Expanding Alhemo to hemophilia without inhibitors recommended - Hemophilia News Today
$3.5-Million Hemophilia Gene Therapy Is World’s Most Expensive Drug - Scientific American
NHS treats first haemophilia B patient with gene therapy - Progress Educational Trust
An Observational Study of Glycopegylated Extended Half-Life Factor Prophylaxis in Hemophilia A and B in a Tertiary Care Center in India - Cureus
A Case of Acquired Hemophilia A and Congenital Hemophilia B - Cureus
G-BA Rates “Considerable” Added Benefit of Alhemo for Hemophilia B Patients - NAVLIN DAILY
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Foreign Language Equivalents
Foreign Language Equivalents of 'haemophilia b'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
gaemophilia b,   haemophilia v,   haemophiloa b,   haemophiliia b,   haemophilia ,   haeemophilia b,   haemopjilia b,   haemophilai b,   harmophilia b,   hhaemophilia b,   haemophliia b,   haemophilis b,   haemoohilia b,   haemophlia b,   haemiphilia b,   haemopholia b,   haemopihlia b,   haemophi;ia b,   jaemophilia b,   haemoophilia b,   haemophili b,   haemophillia b,   aemophilia b,   haemophiia b,   haemophili ab,   haemophilia b,   haemophhilia b,   haemophiila b,   haemmophilia b,   haemophilia bb,   haemophiilia b,   haemophiliab ,   haemophiliaa b,   haemphilia b,   haemohpilia b,   haemophilua b,   haeophilia b,   haemopphilia b,   haenophilia b,   ahemophilia b,   haemophulia b,   hemophilia b,   haemophiliab,   hawmophilia b,   haemopgilia b,   haemophila b,   haempohilia b,   hameophilia b,   haemopilia b,   haaemophilia b,   haemophilia n,   haemophikia b,   haeomphilia b,   hamophilia b,   hae,ophilia b,   hsemophilia b,   heamophilia b,   haemohilia b,   haemo[hilia b,   haempphilia b
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z